Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID‐19

Nicotinamide adenine dinucleotide (NAD+) depletion has been postulated as a contributor to the severity of COVID‐19; however, no study has prospectively characterized NAD+ and its metabolites in relation to disease severity in patients with COVID‐19. We measured NAD+ and its metabolites in 56 hospit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Aging cell 2024-12, Vol.23 (12), p.e14326-n/a
Hauptverfasser:	Valderrábano, Rodrigo J., Wipper, Benjamin, Pencina, Karol Mateusz, Migaud, Marie, Shang, Yili Valentine, Latham, Nancy K., Montano, Monty, Cunningham, James M., Wilson, Lauren, Peng, Liming, Memish‐Beleva, Yusnie, Bhargava, Avantika, Swain, Pamela M., Lehman, Phoebe, Lavu, Siva, Livingston, David J., Bhasin, Shalender
Format:	Artikel
Sprache:	eng
Schlagworte:	1‐methylnicotinamide 2PY Adult Aged Apoptosis Autophagy Cell death Chromatography Chronic illnesses Clinical trials Comorbidity Consent COVID-19 COVID-19 - blood COVID-19 - metabolism COVID-19 - mortality Cytokines Disease DNA biosynthesis DNA repair Female Hospitalization Hospitals Humans Immune response Infections Male Mass spectrometry Metabolites Metabolome Middle age Middle Aged mRNA NAD NAD - blood NAD - metabolism NAD+ augmentation in COVID‐19 NAD+ metabolites NAD+ turnover Niacinamide - analogs & derivatives Niacinamide - blood nicotinamide Observational studies Older people Peripheral blood mononuclear cells Personal health Redox reactions Respiratory distress syndrome SARS-CoV-2 - metabolism SARS‐CoV‐2 infection Scientific imaging Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Transcription Up-regulation Viral infections Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Nicotinamide adenine dinucleotide (NAD+) depletion has been postulated as a contributor to the severity of COVID‐19; however, no study has prospectively characterized NAD+ and its metabolites in relation to disease severity in patients with COVID‐19. We measured NAD+ and its metabolites in 56 hospitalized patients with COVID‐19 and in two control groups without COVID‐19: (1) 31 age‐ and sex‐matched adults with comorbidities, and (2) 30 adults without comorbidities. Blood NAD+ concentrations in COVID‐19 group were only slightly lower than in the control groups (p
ISSN:	1474-9718 1474-9726 1474-9726
DOI:	10.1111/acel.14326